跳转到内容

吡莫地韦

维基百科,自由的百科全书
吡莫地韦
臨床資料
商品名英语Drug nomenclaturePimodivir
法律規範狀態
法律規範
  • Investigational New Drug
识别信息
  • (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
CAS号1629869-44-8
PubChem CID
化学信息
化学式C20H19F2N5O2
摩尔质量399.4
3D模型(JSmol英语JSmol
  • C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O
  • InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
  • Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N

吡莫地韦VX-787JNJ-63623872)是一种抗病毒药,被开发用于治疗流感。它可作为流感病毒聚合酶碱性蛋白2的抑制剂,并在II期临床试验中显示出较好的疗效。[1][2][3]

参考文献

  1. ^ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, Kieffer TL, Leopold L. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2018;23(4):335-344. PMID 29244026doi:10.3851/IMP3212
  2. ^ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, Kosoglou T, Vingerhoets J, Leopold L. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2019 Mar 15;219(7):1026-1034. PMID 30428049doi:10.1093/infdis/jiy547
  3. ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. PMID 30974127 doi:10.1016/j.antiviral.2019.04.006

参见